Influenza Vaccine Market to Reach $6.20 Bn, Globally, by 2026 at 5.9% CAGR: Allied Market Research

PORTLAND, Oregon, Nov. 12, 2019 /PRNewswire/ -- Allied Market Research published a report, titled, "Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Type (Seasonal and Pandemic), Technology (Egg-based and Cell-based), Age Group (Pediatric and Adult), and Route of Administration (Injection and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2019-2026." According to the report, the global influenza vaccine industry garnered $3.96 billion in 2018, and is expected to generate $6.20 billion by 2026, growing at a CAGR of 5.9% from 2019 to 2026.

https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

Drivers, restraints, and opportunities

Surge in prevalence of influenza, technological advancements in administration of vaccines, and focus of governments on immunization programs drive the growth of the global influenza vaccine market. However, high costs related to vaccine development and stringent regulations hinder the market growth. On the other hand, untapped potential in emerging countries and advent of vaccines create new opportunities in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1437

The quadrivalent segment to maintain its lead status by 2026

Based on vaccine type, the quadrivalent segment held nearly two-thirds of the total share of the global influenza vaccine market in 2018, and is estimated to maintain its lead status during the forecast period. Moreover, this segment is projected to portray the largest CAGR of 6.1% from 2019 to 2026. This is due to its cost-effectiveness and its efficacy in offering enhanced protection against four viral strains. The research also analyzes the trivalent segment.

The egg-based segment to dominate in terms of revenue during the forecast period

Based on technology, the egg-based segment accounted for the largest market share in the global influenza vaccine market, accounting nearly 88% of the total share in 2018, and will continue to dominate in terms of revenue during the forecast period. This is due to readily availability of chicken eggs for production of vaccine and its widespread usage in producing inactivated and live attenuated vaccines. Moreover, the cell-based segment is estimated to register the fastest CAGR of 6.5% from 2019 to 2026, owing to availability of cell banking facilities, enhanced protection in comparison to traditional vaccines, and improvement in the effectiveness by eliminating contamination.

North America to maintain its highest contribution during the forecast period

Based on region, North America held the largest market share in 2018, accounting for nearly half of the global influenza vaccine market, and will maintain its highest contribution during the forecast period. This is attributed to rise in prevalence of influenza, increase in focus of governments on immunization programs, and advent of new vaccines. However, LAMEA is expected to portray the highest CAGR of 7.5% from 2019 to 2026. This is due to improvement in healthcare facilities and rapid economic developments in the region.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1437

Market players grabbing the largest pie

    --  AstraZeneca Plc.
    --  Biodiem
    --  CSL Limited
    --  Emergent BioSolutions
    --  F. Hoffmann-La Roche Ltd.
    --  Gamma Vaccines Pty Ltd.
    --  GlaxoSmithKline Plc.
    --  Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
    --  Novartis AG
    --  Pfizer, Inc.
    --  Sanofi Pasteur SA
    --  Sinovac Biotech Ltd.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Self-Monitoring Blood Glucose Devices Market - Global Opportunity Analysis and Industry Forecast, 2018-2025

Spirulina Market - Opportunity Analysis and Industry Forecast, 2019-2026

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research
Follow Us on Twitter: https://twitter.com/marketresearcht

View original content:http://www.prnewswire.com/news-releases/influenza-vaccine-market-to-reach-6-20-bn-globally-by-2026-at-5-9-cagr-allied-market-research-300956146.html

SOURCE Allied Market Research